LivaNova PLC (NASDAQ:LIVN) shares saw strong trading volume on Monday . 273,918 shares traded hands during mid-day trading, an increase of 8% from the previous session’s volume of 252,971 shares.The stock last traded at $60.60 and had previously closed at $59.79.

A number of analysts have issued reports on the stock. WBB Securities reiterated a “hold” rating and issued a $60.00 target price on shares of LivaNova PLC in a research note on Wednesday, August 31st. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $70.00 target price (up from $59.00) on shares of LivaNova PLC in a research note on Friday, August 5th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $67.20.

The stock’s market capitalization is $2.95 billion. The firm has a 50 day moving average price of $60.48 and a 200 day moving average price of $53.78.

In related news, insider Jacques Gutedel sold 4,000 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $60.52, for a total transaction of $242,080.00. Following the completion of the sale, the insider now directly owns 10,948 shares of the company’s stock, valued at approximately $662,572.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Two S.C.A. Equinox sold 75,213 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $59.86, for a total value of $4,502,250.18. The disclosure for this sale can be found here. 0.70% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in LivaNova PLC by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 108,324 shares of the company’s stock worth $5,847,000 after buying an additional 7,607 shares during the last quarter. A.R.T. Advisors LLC boosted its stake in LivaNova PLC by 3.4% in the first quarter. A.R.T. Advisors LLC now owns 54,115 shares of the company’s stock worth $2,921,000 after buying an additional 1,800 shares during the last quarter. BlueMountain Capital Management LLC acquired a new stake in LivaNova PLC during the first quarter worth about $973,000. BNP Paribas Arbitrage SA boosted its stake in LivaNova PLC by 2,043.9% in the second quarter. BNP Paribas Arbitrage SA now owns 18,845 shares of the company’s stock worth $947,000 after buying an additional 17,966 shares during the last quarter. Finally, 1832 Asset Management L.P. boosted its stake in LivaNova PLC by 3.4% in the first quarter. 1832 Asset Management L.P. now owns 54,600 shares of the company’s stock worth $4,922,000 after buying an additional 1,800 shares during the last quarter. 63.67% of the stock is owned by institutional investors and hedge funds.

About LivaNova PLC

LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing.

5 Day Chart for NASDAQ:LIVN

Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.